How to buy Impel NeuroPharma (IMPL) stock

Impel NeuroPharma, Inc is a biotechnology business based in the US. Impel NeuroPharma shares (IMPL) are listed on the NASDAQ and all prices are listed in US Dollars. Impel NeuroPharma employs 59 staff and has a market cap (total outstanding shares value) of 0.00.

Impel NeuroPharma stock price (NASDAQ: IMPL)

Use our graph to track the performance of IMPL stocks over time.

Impel NeuroPharma shares at a glance

• Key figures

Information last updated 2021-07-23.

52-week range	$6.90 - $15.45
50-day moving average	$9.63
200-day moving average	$11.50
Wall St. target price	$29.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Impel NeuroPharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Impel NeuroPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Impel NeuroPharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Impel NeuroPharma financials

Gross profit TTM	$0
Return on assets TTM	-104.31%
Return on equity TTM	-333.3%
Profit margin	0%
Book value	N/A
Market capitalisation	$299.8 million

TTM: trailing 12 months

Shorting Impel NeuroPharma shares

There are currently 580,224 Impel NeuroPharma shares held short by investors – that's known as Impel NeuroPharma's "short interest". This figure is 76.4% up from 328,894 last month.

There are a few different ways that this level of interest in shorting Impel NeuroPharma shares can be evaluated.

Impel NeuroPharma's "short interest ratio" (SIR)

Impel NeuroPharma's "short interest ratio" (SIR) is the quantity of Impel NeuroPharma shares currently shorted divided by the average quantity of Impel NeuroPharma shares traded daily (recently around 110518.85714286). Impel NeuroPharma's SIR currently stands at 5.25. In other words for every 100,000 Impel NeuroPharma shares traded daily on the market, roughly 5250 shares are currently held short.

To gain some more context, you can compare Impel NeuroPharma's short interest ratio against those of similar companies.

• Trevena (TRVN.US): 5.8
• Minerva Neurosciences (NERV.US): 3
• CNS Pharmaceuticals (CNSP.US): 0.38

However Impel NeuroPharma's short interest can also be evaluated against the total number of Impel NeuroPharma shares, or, against the total number of tradable Impel NeuroPharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Impel NeuroPharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Impel NeuroPharma shares in existence, roughly 30 shares are currently held short) or 0.0904% of the tradable shares (for every 100,000 tradable Impel NeuroPharma shares, roughly 90 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Impel NeuroPharma.

Find out more about how you can short Impel NeuroPharma stock.

Impel NeuroPharma share dividends

We're not expecting Impel NeuroPharma to pay a dividend over the next 12 months.

Impel NeuroPharma overview

Impel NeuroPharma, Inc. , a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington. .

Frequently asked questions

What percentage of Impel NeuroPharma is owned by insiders or institutions?
Currently 0.575% of Impel NeuroPharma shares are held by insiders and 66.719% by institutions. How many people work for Impel NeuroPharma?
Latest data suggests 59 work at Impel NeuroPharma. When does the fiscal year end for Impel NeuroPharma?
Impel NeuroPharma's fiscal year ends in December. Where is Impel NeuroPharma based?
Impel NeuroPharma's address is: 201 Elliott Avenue West, Seattle, WA, United States, 98119